强心苷中毒的常规处理方法尚不能令人满意。由于增加强心苷排出量的尝试未获得成功,目前主要依靠支持疗法和心脏起搏法。因而,研制出地高辛抗体以测量药物浓度,并能继而证明抗体在动物体内有清除地高辛毒性的能力将是重要的进展。 1976年地高辛抗体首次用于人体,但因生产问题,严重地限制了供应量。目前,Digi-bind(Wellcome Foundation公司)在英国广泛使用,洋地黄解毒药BM(BoeringherMannheim GmbH)已批准在 The conventional treatment of cardiac glycoside poisoning is not yet satisfactory. Due to unsuccessful attempts to increase the output of cardiac glycosides, the current focus is on supportive therapy and pacing. Thus, the development of digoxin antibodies to measure drug concentration and, in turn, the ability of antibodies to clear digoxin toxicity in animals will be an important advance. Digoxin antibodies were first used in humans in 1976, but supply was severely limited by manufacturing problems. Currently, Digi-bind (Wellcome Foundation) is widely used in the United Kingdom and the digitalis detoxification BM (BoeringherMannheim GmbH)